Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Promoter activity profiling reveals on- and off-target transcriptional responses to drug treatment

ABSTRACT: Promoter activity profiling reveals on- and off-target transcriptional responses to drug treatment

PROVIDER: PRJNA556524 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9829710.fastq.gz	Fastqsanger.gz
	SRR9829720.fastq.gz	Fastqsanger.gz
	SRR9829730.fastq.gz	Fastqsanger.gz
	SRR9829740.fastq.gz	Fastqsanger.gz
	SRR9829750.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 180

Similar Datasets

Promoter activity profiling reveals on- and off-target transcriptional responses to drug treatment

Project description:Owing to safety concerns or insufficient potential for efficacy, only 0.01% to 0.02% of new drug candidates are approved for marketing. Drugs already on the market may be withdrawn or restricted to certain uses due to adverse effects (AEs) discovered after market introduction. Comprehensively investigating the on-/off-target effects of drugs can help expose AEs during the drug development process. In this study, we developed an integrative framework for systematic identification of on-/off-target pathways and elucidation of the underlying mechanisms, by combining expression profiling after drug treatment with gene perturbation of the primary drug target. Expression profiles from statin-treated cells and HMG-CoA reductase knockdowns were analyzed using the framework, allowing for identification of not only reported adverse effects but also novel candidates of off-target effects from statin treatment. Our findings may provide new insights for finding new usages or potential side effects of drug treatment.

2019-07-25 | GSE134817 | GEO

ATLANTIC: Activity landscapes of tumor cell lines determine drug responses

Project description:Analysis of cancer cell line (CCL) genomes, proteomes and phenotypic drug responses are emerging approaches to uncover molecular mechanisms of drug action. We extended this paradigm to measuring proteome activity landscapes by integrating quantitative data for 10,000 proteins and 55,000 phosphorylation sites from 125 CCLs with large drug sensitivity data collections. To engage the scientific community in mining the thousands of novel functional associations generated by this work, we provide an interactive web resource termed ATLANTIC (http://atlantic.proteomics.wzw.tum.de). For instance, we found that Progesterone Receptor (PGR) phosphorylation is a stronger drug response predictor than PGR expression alone in hormone receptor positive breast cancer patients. We also demonstrate that Adenylate kinase isoenzyme 1 (AK1) inactivates chemotherapeutic drugs such as Cytarabine. Consequently, high AK1 levels correlated with poor survival of Cytarabine-treated acute myelogenous leukemia patients qualifying AK1 as a treatment stratification and drug response marker and possibly as a drug target.

2020-07-27 | PXD013615 | Pride

Capturing drug responses by quantitative promoter activity profiling

Project description:Quantitative analysis of cellular responses to signaling inhibitors. Total RNA obtained from MCF7 human breast cancer cell lines treated with 1uM gefitinib, 500nM U0126 or 10nM wortmannin for 6hr.

2013-07-10 | E-GEOD-48652 | biostudies-arrayexpress

PfAP2-G target gene promoter mutants expression timecourse

Project description:PfAP2-G target gene promoter mutants expression timecourse

| PRJNA497051 | ENA

Cardiac precursor differentiation from hESCs by lentiviral promoter drug selection

Project description:Several of the essential core transcriptional control elements in human embryonic stem cells (ESCs) have been identified, but the production and function of alternative isoforms in self-renewal, pluripotency and tissue lineage specification remain largely unknown. We have modified the H9 ESC line to allow for drug selection of human pluripotent ESCs and cardiac progenitors. Exon-level microarray expression data from undifferentiated ESCs and day 40 cardiac precursors were used to identify differentially expressed and alternative splice isoforms during differentiation. Keywords: comparison RNA from a homogenous population of undifferentiated hESCs (REX1-neo promoter drug selection) and differentiated day 40 cardiomyocytes (alpha MHC-puro promoter drug selection) was isolated and profiled with exon-tiling arrays.

2008-10-24 | E-GEOD-13297 | biostudies-arrayexpress

Capturing drug responses by quantitative promoter activity profiling

Project description:Quantitative analysis of cellular responses to signaling inhibitors.

2013-07-10 | GSE48652 | GEO

Capturing drug responses by quantitative promoter activity profiling.

Project description:Quantitative analysis of cellular responses to drugs is of major interest in pharmaceutical research. Microarray technologies have been widely used for monitoring genome-wide expression changes. However, this approach has several limitations in terms of coverage of targeted RNAs, sensitivity, and quantitativeness, which are crucial for accurate monitoring of cellular responses. In this article, we report an application of genome-wide and quantitative profiling of cellular responses to drugs. We monitored promoter activities in MCF-7 cells by Cap Analysis of Gene Expression using a single-molecule sequencer. We identified a distinct set of promoters affected even by subtle inhibition of the Ras-ERK and phosphatidylinositol-3-kinase-Akt signal-transduction pathways. Furthermore, we succeeded in explaining the majority of promoter responses to inhibition of the upstream epidermal growth factor receptor kinase quantitatively based on the promoter profiles upon inhibition of the two individual downstream signaling pathways. Our results demonstrate unexplored utility of highly quantitative promoter activity profiling in drug research.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e77; doi:10.1038/psp.2013.53; published online 25 September 2013.

| S-EPMC4026637 | biostudies-literature

Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia

Project description:We identified novel nicotinamide-based FLT3 inhibitors ( HSN748) that specifically target FLT3-ITD at sub-nanomolar concentrations and are effective against drug-resistant secondary mutations. In the current study, we evaluated these compounds’ antileukemic activity against FLT3-ITD and gatekeeper mutations in drug-resistant AML, relapsed/refractory AMLs with FLT3 mutations

2024-06-15 | GSE221459 | GEO

Capturing drug responses by quantitative promoter activity profiling

| S-ECPF-GEOD-48652 | biostudies-other

Low CAG promoter activity enriches for reprogramming progressive cells

Project description:Low CAG promoter activity enriches for reprogramming progressive cells

| PRJNA662363 | ENA